Petrova NL, Donaldson NK, Bates M, et al. - In this study, the efficacy of recombinant human parathyroid hormone (PTH) in reducing time to resolution of Charcot neuro-osteoarthropathy (CN) and healing of fractures was explored. Researchers randomized people with diabetes and acute (active) Charcot foot to either full-length PTH (1-84) or placebo therapy, both in addition to below-knee casting and calcium and vitamin D3 supplementation. The primary endpoint included resolution of CN, defined as a skin foot temperature difference > 2°C at two consecutive monthly visits. It has been reported that this double-blind placebo-controlled trial did not reduce time to resolution or enhance fracture healing of CN. No added benefit of daily intervention with PTH (1-84) to below-knee casting in achieving earlier resolution of CN was observed.